Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescr

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering.


This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Eli Lilly's performance against key rivals in the prescription pharmaceutical sector
  • Assess the commercial outlook for key new launch products Effient and Bydureon
  • Evaluate Eli Lilly's ability to overcome the adverse impact of patent expiry for Zyprexa, Cymbalta and other key franchises over the period 2011-14

Key Topics Covered:

Chapter 1 About this profile

Chapter 2 Executive summary Chapter 3 Quarterly news update

Chapter 4 Company introduction

Chapter 5 Company sales

Chapter 6 Company financials

Chapter 7 Key products and competitors

Chapter 8 Appendix

Companies Mentioned:

  • Abbott Laboratories
  • ACS Motion Control Ltd
  • Alkermes Inc
  • Amylin Pharmaceuticals Inc
  • AstraZeneca PLC
  • Automatic Data Processing, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cephalon
  • Chugai Pharmaceutical Co. Ltd
  • Citizen Electronics Company Limited
  • Daiichi Sankyo, Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Impax Laboratories, Inc.
  • IMS Health
  • Johnson & Johnson
  • Merck & Co., Inc.
  • NICE Systems Ltd
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Pivotal Corporation

For more information visit

Source: Datamonitor


Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Pharmaceutical



Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.